Direct Medical Costs of Diabetes and the Foot Ulcer Outpatients in A General Hospital, Yogyakarta

https://doi.org/10.22146/jmpf.90615

Eka Kartika Untari(1), Tri Murti Andayani(2*), Nanang Munif Yasin(3), Rizka Humardewayanti Asdie(4)

(1) *) Doctoral Graduate Program, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, 55281 *) Pharmacy Department, Medical Faculty of Tanjungpura University, Pontianak, West Kalimantan, 78115
(2) Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Yogyakarta, 55281
(3) Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Yogyakarta, 55281
(4) Department of Internal Medicine, Faculty of Medicine, Pubic Health, and Nursing, Gadjah Mada University-dr. Sardjito Hospital, Jalan Kesehatan Sekip no.1, Yogyakarta, 55281
(*) Corresponding Author

Abstract


Background: In addition to the financial burden that Diabetes Mellitus (DM) places on diabetics and their families due to the complications of Diabetic Foot Ulcers (DFU), treatment costs are escalating. Along with the costs associated with diabetic impairments, direct medical costs may contribute significantly to the financial burden of diabetes.

Objectives: This study aimed to determine expenditures associated with DFU, identify cost-influencing factors, and compare the costs of patients with DFU and those without ulcers.

Methods: To achieve this objective, this study employed a cross-sectional design and included 198 medical records of DM patients who met the following criteria: age range of 18 to 60 years; type 1 or type 2 DM; receipt of anti-diabetics; payment information; absence of autoimmune or end-stage chronic disease; and absence of corticosteroid. The significance of the cost difference between DFU and non-ulcer patients was evaluated using parametric and non-parametric tests as well as linear regression analysis to determine the cost-influencing factors.

Results: This study included 188 patients with type 2 diabetes and ten patients with type 1 diabetes. A total of 131 people with diabetes did not have ulcers, while 67 had a history of DFU. The average direct medical expenses for patients with DFU are IDR 760,146.32, compared to IDR 542,51.24 for patients without ulcer.

Conclusion: The presence of ulcers and glycemic conditions had an effect on the direct costs; insulin use also affected the direct costs. The direct costs of diabetic ulcer were significantly higher than non-ulcer, and they were predominantly affected by insulin prescribing.


Keywords


Diabetic foot; Diabetes; Direct Medical Costs; Insulin

Full Text:

PDF


References

  1. IDF. Diabetes Atlas 10th Edition. International Diabetes Federation; 2021. https://diabetesatlas.org/atlas/tenth-edition/
  2. Choi JW, Choi JW, Kim JH, Yoo KB, Park EC. Association between chronic disease and catastrophic health expenditure in Korea. BMC Health Serv Res. 2015;15(1):26. doi:10.1186/s12913-014-0675-1
  3. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJ. Household catastrophic health expenditure: a multicountry analysis. The Lancet. 2003;362(9378):111-117. doi:10.1016/S0140-6736(03)13861-5
  4. Ratnasari PMD, Andayani TM, Endarti D. Analisis Outcome Klinis Berdasarkan Kualitas Hidup dan Biaya Medik Langsung Pasien Diabetes Melitus Tipe 2. J Sains Farm Klin. 2020;7(1):15. doi:10.25077/jsfk.7.1.15-22.2020
  5. Baroroh F, Solikah WY, Urfiyya A. ANALISIS BIAYA TERAPI DIABETES MELITUS TIPE 2 DI RUMAH SAKIT PKU MUHAMMADIYAH BANTUL YOGYAKARTA. 2016;(2).
  6. Peters ML, Huisman EL, Schoonen M, Wolffenbuttel BHR. The current total economic burden of diabetes mellitus in the Netherlands. Neth J Med. 2017;75(7).
  7. Bommer C, Heesemann E, Sagalova V, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017;5(6):423-430. doi:10.1016/S2213-8587(17)30097-9
  8. Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update. Endocrine Practice. 2022 Oct 1;28(10):923-1049.
  9. Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis. Ann Med. 2017;49(2):106-116. doi:10.1080/07853890.2016.1231932
  10. Yazdanpanah L, Shahbazian H, Nazari I, Arti HR, Ahmadi F, Mohammadianinejad SE, Cheraghian B, Hesam S. Incidence and risk factors of diabetic foot ulcer: a population‐based diabetic foot cohort (ADFC study)—two‐year follow‐up study. International journal of endocrinology. 2018;2018(1):7631659.
  11. Blair M. Diabetes Mellitus Review. Urol Nurs. 2016;36(1):27-36. doi:10.7257/1053-816X.2016.36.1.27
  12. Wu H, Eggleston KN, Zhong J, et al. How do type 2 diabetes mellitus (T2DM)-related complications and socioeconomic factors impact direct medical costs? A cross-sectional study in rural Southeast China. BMJ Open. 2018;8(11):e020647. doi:10.1136/bmjopen-2017-020647
  13. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917-928. doi:10.2337/dci18-0007
  14. Hicks CW, Selvarajah S, Mathioudakis N, et al. Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers. J Vasc Surg. 2014;60(5):1247-1254.e2. doi:10.1016/j.jvs.2014.05.009
  15. Jodheea-Jutton A, Hindocha S, Bhaw-Luximon A. Health economics of diabetic foot ulcer and recent trends to accelerate treatment. The Foot. 2022;52:101909. doi:10.1016/j.foot.2022.101909
  16. RL Schaeffer, Mendenhall W, Otto L. Elementary Survey Sampling. Duxburry Press; 1990.
  17. Priyanto MH, Legiawati L, Saldi SRF, Yunir E, Miranda E. Comparison of vitamin D levels in diabetes mellitus patients with and without diabetic foot ulcers: An analytical observational study in Jakarta, Indonesia. Int Wound J. 2023;20(6):2028-2036. doi:10.1111/iwj.14066
  18. Zhu X, Lee M, Chew EA, Goh LJ, Dong L, Bartlam B. “When nothing happens, nobody is afraid!” beliefs and perceptions around self‐care and health‐seeking behaviours: Voices of patients living with diabetic lower extremity amputation in primary care. International Wound Journal. 2021 Dec;18(6):850-61.
  19. Mursalin M, Soewondo P. Analisis Estimasi Biaya Langsung Medis Penderita Rawat Jalan Diabetes Mellitus Tipe 2 di RSUD Dr. Abdul Aziz Singkawang Tahun 2013. J Ekon Kesehat Indones. 2017;1(2). doi:10.7454/eki.v1i2.1770
  20. Chen HY, Kuo S, Su PF, Wu JS, Ou HT. Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up. Diabetes Care. 2020;43(8):1732-1740. doi:10.2337/dc20-0072
  21. Jia L, Parker CN, Parker TJ, et al. Incidence and risk factors for developing infection in patients presenting with uninfected diabetic foot ulcers. Jan YK, ed. PLOS ONE. 2017;12(5):e0177916. doi:10.1371/journal.pone.0177916
  22. Al-Maskari F, El-Sadig M, Nagelkerke N. Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates. BMC Public Health. 2010;10(1):679. doi:10.1186/1471-2458-10-679
  23. KRISTINA SA, Endarti D, ANDAYANI TM, WIDAYANTI AW. Direct and Indirect Cost of Diabetes Mellitus in Indonesia: A Prevalence Based Study with Human Capital Approach. Int J Pharm Res 09752366. 2021;13(1).
  24. Walker IF, Garbe F, Wright J, et al. The Economic Costs of Cardiovascular Disease, Diabetes Mellitus, and Associated Complications in South Asia: A Systematic Review. Value Health Reg Issues. 2018;15:12-26. doi:10.1016/j.vhri.2017.05.003
  25. Lo ZJ, Surendra NK, Saxena A, Car J. Clinical and economic burden of diabetic foot ulcers: A 5‐year longitudinal multi‐ethnic cohort study from the tropics. Int Wound J. 2021;18(3):375-386. doi:10.1111/iwj.13540
  26. Zhuo X, Zhang P, Hoerger TJ. Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications. Am J Prev Med. 2013;45(3):253-261. doi:10.1016/j.amepre.2013.04.017
  27. ADA. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S125-S143. doi:10.2337/dc22-S009
  28. ADA. 7. Diabetes Technology: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S97-S112. doi:10.2337/dc22-S007



DOI: https://doi.org/10.22146/jmpf.90615

Article Metrics

Abstract views : 2124 | views : 1603

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats